Genetic doping is no longer theoretical; 92% of athletes underwent anti-doping testing before the Winter Olympics 2026. Experts propose genomic passports, noting no confirmed cases but black-market availability of plasmid-based EPO genes.
IDT's study showed UNCOVERseq achieved 97.6% sensitivity and 78% precision for CRISPR off-target nomination. Scribe will present new data at ASGCT and EAS, including STX-1150. Watchmaker licensed CRISPR-Cas9 IP for NGS normalization.
Sana Biotechnology stock gapped up over 13% on Tuesday after beating Q1 earnings estimates, continuing a Monday rally. Analysts reaffirmed a Moderate Buy consensus with a $9.50 target, as institutional ownership remains high at 88%.
In vivo base editing corrected the CHD3 p.R1025W mutation in a mouse model of Snijders Blok–Campeau syndrome, restoring protein levels and rescuing behavioural abnormalities. Intrathecal AAV delivery in nonhuman primates supported translational feasibility.
Researchers report advances in RNA-based gene therapy: an FDA-approved small molecule modulates RNA splicing, protein-coated nanoparticles enable safer delivery, and a microRNA platform targets glioblastoma.
A 2026 review outlines the shift in solid organ transplantation from broad immunosuppression to Treg-based active tolerance. It covers polyclonal Tregs, CAR-Tregs and CRISPR-edited off-the-shelf products.
A seminar will present work on KRAS-driven lung cancer and immunotherapy resistance. The research uses immune-competent mouse models and CRISPR-Cas9 screens to identify targets that sensitise tumour cells to T cell-mediated killing.
Scientists have developed two breakthrough approaches to dramatically enhance gene editing and mRNA therapy delivery: a simple amino acid supplement that increases CRISPR efficiency to nearly 90 percent, and a self-replicating CRISPR system that spreads between cells like a virus.
Researchers unveil tumor-intrinsic role of PD-L1 in lung cancer progression and develop systematic method for discovering molecular glues that selectively degrade disease proteins, while advances in immunology research aim to improve care for immune-mediated inflammatory diseases.
Transposase systems are emerging as efficient alternatives to CRISPR-Cas9 for gene editing in biopharmaceutical manufacturing and plant breeding, with studies showing up to 90% efficiency and heritability rates while offering advantages in size and integration capabilities.
